BIO-KOREA
13.5.2020 06:36:05 CEST | Business Wire | Press release
The BIO KOREA Organizing Committee announced it will hold the BIO KOREA 2020 International Convention scheduled for May 18–23 as an online convention instead of an in-person event for this year.
The decision was based on the impact of COVID-19, the safety of the attendees and global health recommendations regarding large, in-person gatherings.
BIO KOREA 2020 Online Convention
- Date: May 18 09:00 to 23 18:00 (KST)
- Point of Access: www.biokorea.org
- Program: Online Business Forum with Partnering, Virtual Exhibition, e-Conference, Invest Fair, Job Fair
Online Business Forum with Partnering
BIO KOREA 2020 Online Convention will focus on the virtual collaboration with its Partnering system allowing attendees to schedule virtual meetings to maximize their business development and licensing potential. International participation continues to grow. Numerous companies from 20+ countries are already joined and expected to showcase their advanced technologies at BIO KOREA 2020.
Definitely expecting to be a place where various kinds of discussion will be held, with Korean companies as not just the companies which are leading bio industry in Korea such as LG Chem Life Science, Samsung Biologics, Celltrion, and Hanmi Pharmaceuticals, etc., also promising SMEs like Organoid Science, YBRAIN, and Amyloid Solution are attending to foster their business. And 24-hour meeting slots will let strengthen your digital network across time zones.
Virtual Exhibition
The new format includes Virtual Exhibition where has set to show the cutting-edge technologies and products of exhibitors in various ways such as Digital Scan, Animation, 360° VR, and so on. 350+ exhibitors, from start-up to the global enterprise, will be at BIO KOREA's virtual exhibition and also there will be COVID-19 Special Zone to introduce South Korea's effective diagnostic tests, high-tech medical technology, and protocols.
e-Conference
The conference of BIO KOREA will also come with the online format under the theme of “A New Paradigm in the Age of Data Science” including expert-level content focused on the most pressing industry topics including COVID-19, Vaccine, Alzheimer’s Disease, Electroceutical, Digital Pathology, Digital Therapeutics, AI (Artificial Intelligence). BIO KOREA 2020’s e-Conference, covering 13 topics with 90+ speakers, will bring the most up-to-date conversations in biopharma to your home office.
Invest Fair
Invest Fair is an event where pharmaceuticals, bio, and healthcare companies that are advancing into the global market and developing new drugs introduce their superior technology and investors to the companies’ vision and strategy. Along with online hosting, it maintains its attendance by impressive lineups of 24 companies such as GC Greencross, Celltrion, Tium BIO, and ABL Bio.
Job Fair
Aiming to place its main objective in recruiting talented individuals amongst undergraduates and postgraduates searching for job vacancies in bio industry, companies participating in Job Fair will share their success tips in various fields. Amid current bleak jobs pictures, about 30 companies are attending with 150+ job openings.
Lastly, BIO KOREA remains committed to amplifying the industry’s efforts to develop solutions for patients. In response to the COVID-19 pandemic, the special sessions dealing with its diagnostic kits, therapeutics and vaccines, also sharing the cooperation among the governments, industries are prepared. Jerom Kim from IVI will deliver the Keynote speech for the COVID-19 special session.
For more information, visit BIO KOREA’s Official Website: www.biokorea.org
View source version on businesswire.com: https://www.businesswire.com/news/home/20200512005997/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Tecnotree Reports Stable Revenue and Strong Profitability in Q1 2026 and Maintains Full-Year Guidance29.4.2026 14:06:00 CEST | Press release
Tecnotree, a global digital platform and services provider for AI-enabled 5G and cloud-native technologies, today announced its financial results for the first quarter of 2026, demonstrating stable revenue, strong profitability, and a robust order backlog despite geopolitical uncertainties across global markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429319948/en/ Tecnotree Reports Stable Revenue and Strong Profitability in Q1 2026 and Maintains Full-Year Guidance Key Financial Highlights – Q1 2026 Revenue of EUR 16.8 million (16.9), revenue in constant currency EUR 17.1 million, +1.0% YoY. EBIT of EUR 4.6 million (4.5), +1.8% YoY. EBIT margin of 27.4% (26.9%), +50 basis points YoY. Foreign exchange (FX) gains EUR 1.0 million (-1.4). Net income EUR 2.1 million (1.5), +36.5% YoY. Free cash flow (FCF) EUR 0.2 million (1.0). Earnings per share (EPS) EUR 0.1 (0.1). Order book at the end of the period EUR 105.4 million
SS&C Unveils WorkHQ to Power Enterprise Agentic Automation29.4.2026 14:00:00 CEST | Press release
Agentic automation platform enables companies to control, govern and accelerate enterprise-wide adoption of AI SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced the launch of SS&C Blue Prism WorkHQ, its agentic automation platform designed to help enterprises operationalize agentic AI safely, transparently and with full control of end-to-end workflows. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429512507/en/ Unveiled at a live event at Nasdaq in New York City, WorkHQ introduces a unified control plane orchestrating people, AI agents, APIs and digital workers into a single governed environment. SS&C developed WorkHQ based on its own experience operating at scale across regulated industries. Today, SS&C supports more than 23,000 customers globally with the help of 4,000+ digital workers and more than 50 AI agents. These efforts have enabled SS&C to significantly improve operational efficiency in key proces
Ecolab Life Sciences Expands Global Bioprocessing Capabilities With New Advanced Development and Applications Center in Korea29.4.2026 14:00:00 CEST | Press release
New facility brings deep expertise closer to Asian customers, strengthening Ecolab’s global network Building on the continued growth and strong performance of its Life Sciences business, Ecolab is further expanding its global bioprocessing capabilities to support biopharmaceutical manufacturers worldwide. Today, Ecolab Life Sciences announced the opening of a new Bioprocessing Applications Lab (BPAL) in Dongtan, Korea, its first bioprocessing facility in Asia. The new center further strengthens the company’s global Life Sciences footprint and supports customers operating in one of the world’s most advanced biopharmaceutical manufacturing markets. The Korea BPAL supports a full range of process development activities from early-stage testing through studies that replicate manufacturing at scale, building on Ecolab’s established bioprocessing applications network in the United States and the United Kingdom. The facility enables hands-on collaboration with Ecolab’s bioprocessing experts t
Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio29.4.2026 13:42:00 CEST | Press release
Highlights: Chiesi agreed to acquire KalVista Pharmaceuticals for $27.00 per share in cash, representing an equity consideration of approximately $1.9bnAcquisition adds to Chiesi’s rare immunology portfolio the first oral, on-demand therapy for hereditary angioedema, strengthening Chiesi’s long-term commitment to people living with rare conditionsTransaction expected to close in Q3 2026 Chiesi Group (“Chiesi”), an international research-focused biopharmaceutical group and certified B Corp, and KalVista Pharmaceuticals, Inc.(“KalVista”) (Nasdaq: KALV), today announced that the companies have entered into a definitive agreement under which Chiesi will acquire KalVista (the “Transaction”). The Transaction was unanimously approved by both Chiesi’s and KalVista’s Boards of Directors and is expected to close in Q3 2026, subject to the satisfaction of customary closing conditions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202604
Pacific Defense Awarded U.S. Marine Corps Contract for Next Generation Electronic Warfare Prototype29.4.2026 13:00:00 CEST | Press release
Award advances SOSA/CMOSS mission system ecosystem and informs future EW fielding decisions Pacific Defense has been awarded a 12-month rapid prototyping contract by the U.S. Marine Corps Systems Command (MARCORSYSCOM), Program Manager for Tactical Communications and Electronic Warfare (PM TCE) to support next-generation electronic warfare (EW) capability evaluation. The effort will assess Modular Open Systems Approach (MOSA) Electronic Warfare (EW) mission systems and their potential in modernizing USMC capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429918712/en/ Pacific Defense's Next Generation Electronic Warfare System enables rapid integration of new hardware and software into a common chassis, accelerating capability insertion while reducing vendor lock and lifecycle costs. Under the contract, Pacific Defense will deliver SOSA/CMOSS-aligned mission systems to enable vehicle-based experimentation by U.S
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom